| abstract |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolated form or in mixtures, wherein each occurrence of R 1 and R 2 is independently at each occurrence; an oxygen atom in the form of a nitro group or an oxime; an amino group, -SO 3 -R or an organic group containing 1 to 6 heteroatoms selected from nitrogen, oxygen, phosphorus, silicon and sulfur, or R 2 is a direct bond in SEQ ID NO: 3; or R 1 and R 2 taken together with the nitrogen atom to which they are attached form a heterocyclic ring, or R 1 may represent a 2 or 3 atom chain attached to atom 2 to form -N-R 1 - a fused bicyclic moiety; R 3 and R 4 may be a direct bond to atoms 6 and 7, or may be hydrogen or a protecting group, each of numbers 1-17 being carbon atoms where 1, 2, 4, Carbon atoms 11, 12, 15, 16, 17 can be optionally substituted (a) by a = O, = C (R5) (R5), = C = C (R5) ( R 5), -C (R 5) (R 5) C (R 5) (R 5) n - or - (O (C (R 5) (R 5)) n O) -, wherein n is 1-6; ) with two groups independently selected from -X, -N (R 1) (R 2), -R 5 and -OR 6; and carbon atoms 5, 8, 9, 10, 13 and 14 may be independently substituted with -X, -R 5, -N (R 1) (R 2) or -OR 6; in addition to -OR3 and -OR4, carbon numbers 6 and 7 may be independently substituted with -X, -N (R1) (R2), -R5, or -OR6; and each of the rings A, B, C and D can be independently saturated, partially saturated, or completely unsaturated. The aforementioned compounds can be formulated in a pharmaceutical composition and used for the treatment and / or prevention of various diseases such as inflammation, asthma, allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, hard tumors, AIDS, ischemia and cardiac arrhythmias. HE |